Furthermore, we also demonstrated that hematological cancers such as T-anaplastic large cell lymphoma30,31 and multiple myeloma32 are also potential targets of CD26-directed therapies as well as MPM and RCC. This evidence concerns the gene DPP4 and renal cell adenocarcinoma.